Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis

Vaccine ◽  
2001 ◽  
Vol 19 (28-29) ◽  
pp. 3834-3842 ◽  
Author(s):  
C.A Hanlon ◽  
C.A DeMattos ◽  
C.C DeMattos ◽  
M Niezgoda ◽  
D.C Hooper ◽  
...  
2016 ◽  
Vol 8 (4) ◽  
pp. 407-421 ◽  
Author(s):  
Paola De Benedictis ◽  
Andrea Minola ◽  
Elena Rota Nodari ◽  
Roberta Aiello ◽  
Barbara Zecchin ◽  
...  

Virology ◽  
2007 ◽  
Vol 358 (1) ◽  
pp. 69-78 ◽  
Author(s):  
Flavia Ferrantelli ◽  
Kathleen A. Buckley ◽  
Robert A. Rasmussen ◽  
Alistair Chalmers ◽  
Tao Wang ◽  
...  

AIDS ◽  
2003 ◽  
Vol 17 (3) ◽  
pp. 301-309 ◽  
Author(s):  
Flavia Ferrantelli ◽  
Regina Hofmann-Lehmann ◽  
Robert A Rasmussen ◽  
Tao Wang ◽  
Weidong Xu ◽  
...  

Author(s):  
Martin L. Nelwan

Rabies is one of the neglected tropical diseases, almost 100% fatal, but preventable. Rabies virus causes the disease and causes about 59000 human deaths annually. The author searched the Pubmed Database at NCBI for articles on rabies disease published between 2007 and 2018. All articles are open access, free for redistribution and in English. To examine rabies virus, Seller’s test was used. In this article, references written by the author were included and relevant publications were also included. The author reviewed a rabies dog case kept at Nelwan Institution for Human Resource Development. The dog showed clinical signs such as aggressive behavior, in-appetence, and soaking in water. Currently, there are no drugs to treat rabies. Vaccination is the best way to prevent the disease. To eradicate rabies, mass vaccination in dogs, post-exposure prophylaxis, and gene therapy can be used. To prevent rabies disease, minimum 70% of the dog population should receive vaccination. Humans with category II exposure should receive rabies vaccine and rabies immunoglobulin. For treatment, in vivo experiment showed that gene therapy can eliminate rabies from the infected neurons by using rAAV-N796. To fight rabies virus, induced pluripotent cells in combination with CRISPR/Cas9 system can also be beneficial. Furthermore, it needs US$ 8.6 billion to fight rabies annually.


Author(s):  
Dawn Weir ◽  
Si'Ana Coggins ◽  
Bang Vu ◽  
Jessica Coertse ◽  
Lianying Yan ◽  
...  

Australian bat lyssavirus (ABLV) is a rhabdovirus that circulates in four species of pteropid bats (ABLVp) and the yellow-bellied sheath-tailed bat (ABLVs) in mainland Australia. In the three confirmed human cases of ABLV, rabies illness preceded fatality. As with rabies virus (RABV), post-exposure prophylaxis (PEP) for potential ABLV infections consists of wound cleansing, ad-ministration of the rabies vaccine and injection of rabies immunoglobulin (RIG) proximal to the wound. Despite the efficacy of PEP, the inaccessibility of human RIG (HRIG) in the developing world and the high immunogenicity of equine RIG (ERIG) has led to consideration of human monoclonal antibodies (hmAbs) as a passive immunization option that offers enhanced safety and specificity. Using a recombinant vesicular stomatitis virus (rVSV) expressing the glycoprotein (G) protein of ABLVs and phage display, we identified two hmAbs, A6 and F11, which completely neutralize ABLVs/ABLVp, and RABV at concentrations ranging from 0.19-3.12 µg/mL and 0.39-6.25 µg/mL respectively. A6 and F11 recognize overlapping epitopes in the lyssavirus G protein, ef-fectively neutralizing phylogroup 1 lyssaviruses, while having little effect on phylogroup 2 and non-grouped diverse lyssaviruses. These results suggest A6 and F11 could be effective therapeutic and diagnostic tools for phylogroup 1 lyssavirus infections.


2020 ◽  
Vol 5 (1) ◽  
pp. 40 ◽  
Author(s):  
Thomas Moulenat ◽  
Céline Petit ◽  
Valérie Bosch Castells ◽  
Guy Houillon

The purified Vero cell rabies vaccine (PVRV; Verorab®, Sanofi Pasteur) has been used in rabies prevention since 1985. Evolving rabies vaccination trends, including shorter intradermal (ID) regimens with reduced volume, along with WHO recommendation for ID administration has driven recent ID PVRV regimen assessments. Thus, a consolidated review comparing immunogenicity of PVRV ID regimens during pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) is timely and beneficial in identifying gaps in current research. A search of seven databases for studies published from 1985 to November 2019 identified 35 studies. PrEP was assessed in 10 studies (n = 926) with 1–3-site, 1–3-visit regimens of up to 3-months duration. Seroconversion (rabies virus neutralizing antibodies [RVNA] ≥ 0.5 IU/mL) rates of 90–100% were reported within weeks, irrespective of regimen, with robust booster responses at 1 year (100% seroconversion rates by day 14 post-booster). However, data are lacking for the current WHO-recommended, 2-site, 1-week ID PrEP regimen. PEP was assessed in 25 studies (n = 2136) across regimens of 1-week to 90-day duration. All ID PEP regimens assessed induced ≥ 99% seroconversion rates (except in HIV participants) by day 14–28. This review confirms ID PVRV suitability for rabies prophylaxis and highlights the heterogeneity of use in the field.


Sign in / Sign up

Export Citation Format

Share Document